Tüdőrák: vizsgálatok itt: Kína

In Kína 1144 Also abroad 2746

1144 trials · From ClinicalTrials.gov, checked 2026. november 15.. Ask the study team whether a trial fits you.

No phaseTaking people
ePRO in Advanced Lung Cancer: Emotional Distress, Symptom Burden, Brain Metastasis
Where
Hubei
Életkor
18 év and over
People
200
Run by
Qian Chu
See details and how to joinNCT07912190
1. fázisNot yet taking people in Kína
Study of SIM0518 in Participants With ALK-Positive or ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Where
Changchun, Changsha, Fuzhou, Harbin, Nanchang, Shanghai, Taizhou
Életkor
18 év and over
People
270
Run by
Jiangsu Simcere Pharmaceutical Co., Ltd.
See details and how to joinNCT07912268
1/2. fázisNot yet taking people in Kína
Antigen-specific T Cells Against Lung Cancer
Where
Shenzhen
Életkor
18 év to 80 év
People
20
Run by
Shenzhen Geno-Immune Medical Institute
See details and how to joinNCT03356808
2. fázisTaking people
A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC
Where
Beijing, Chengdu, Guangzhou, Hangzhou, Harbin, Jinan, Nanchang, Nanjing, Qujing, Shanghai, Wuhan, Zhengzhou
Életkor
18 év and over
People
66 worldwide
Run by
Teligene US
See details and how to joinNCT06010329
1. fázisTaking people
A Study of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tumors and Other Solid Tumors
Where
Shanghai
Életkor
18 év to 75 év
People
115
Run by
Biokin (Shanghai) Biopharmaceutical Co., Ltd.
See details and how to joinNCT06505824
2/3. fázisTaking people
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
Where
Baoding, Beijing, Bengbu, Changchun, Changsha, Hangzhou, Jiamusi, Jinan, Kunming, Nanjing, Shanghai, Shantou, Suzhou, Wanzhou, Wuhan, Yangzhou, Zhejiang
Életkor
18 év and over
People
1580 worldwide
Run by
BioNTech SE
See details and how to joinNCT06712316 · EU 2024-515764-31-00
3. fázisTaking people
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Where
Beijing, Changsha, Chengdu, Chongqing, Dalian, Foshan, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Hohhot, Jinan, Kunming, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Nantong, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Weifang, Wuhan, Xiamen, Xinxiang, Yibin, Zhengzhou
Életkor
18 év and over
People
480 worldwide
Run by
ArriVent BioPharma, Inc.
See details and how to joinNCT07185997
3. fázisTaking people
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
Where
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Jinan, Kunming, Linyi, Nanchang, Nanjing, Ningbo, Shanghai, Shijiazhuang, Suzhou, Taizhou, Tianjin, Wuhan, Xuzhou, Yangzhou, Zhengzhou
Életkor
18 év and over
People
400 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07195695 · EU 2025-521284-12-00
3. fázisTaking people
A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer
Where
Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Luzhou, Nanchang, Nanjing, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wenzhou, Xi’an, Xinxiang, Xuzhou, Zhengzhou
Életkor
18 év and over
People
1200 worldwide
Run by
Takeda
See details and how to joinNCT07217301 · EU 2026-525659-94-00
2. fázisTaking people
A Study of BL-M14D1 in Combination With Atezolizumab in Patients With Extensive-stage Small Cell Lung Cancer
Where
Shanghai
Életkor
18 év and over
People
36
Run by
Biokin (Shanghai) Biopharmaceutical Co., Ltd.
See details and how to joinNCT07654400
3. fázisTaking people
Phase III Study of HS-10504 Versus Platinum-Based Doublet Chemotherapy in Patients With C797S+ NSCLC
Where
Guangzhou
Életkor
18 év and over
People
206
Run by
Jiangsu Hansoh Pharmaceutical Co., Ltd.
See details and how to joinNCT07754123
2/3. fázisTaking people
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Where
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Linyi, Liuzhou, Luzhou, Nanchang, Nanjing, Nanning, Nantong, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Taiyuan, Taizhou, Ürümqi, Wuhan, Xiamen, Xi'an, Xinxiang, Xuzhou, Yinchuan, Zhengzhou
Életkor
18 év and over
People
626 worldwide
Run by
Mirati Therapeutics Inc.
See details and how to joinNCT04613596 · EU 2023-508922-83-00
3. fázisTaking people
A Study Comparing QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy in Participants Wih Treatment-naïve Extensive-Stage Small Cell Lung Cancer
Where
Shanghai
Életkor
18 év and over
People
556
Run by
Qilu Pharmaceutical Co., Ltd.
See details and how to joinNCT07802821
No phaseTaking people
Exploration of Whole-Brain Radiotherapy Combined With PD-1 Inhibitors on Brain Injury
Where
Guiyang
Életkor
18 év to 75 év
People
42
Run by
Guizhou Medical University
See details and how to joinNCT07905937
3. fázisTaking people
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Where
Baoding, Beijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Hohhot, Jinan, Kunming, Linhai, Linyi, Nanchang, Nanjing, Nanning, Nantong, Nanyang, Ningbo, Shanghai, Shantou, Shenyang, Taiyuan, Tianjin, Ürümqi, Wuhan, Xiamen, Xi'an, Zhanjiang, Zhengzhou
Életkor
18 év and over
People
768 worldwide
Run by
AbbVie
See details and how to joinNCT04928846 · EU 2023-505749-14-00
2. fázisTaking people
PirfenidoneVsPlacebo as Prophylaxis Against Acute Radiation-induced Lung Injury Following HFRT in Breast Cancer Patients
Where
Fuzhou
Életkor
18 év to 75 év
People
214
Run by
Fujian Medical University Union Hospital
See details and how to joinNCT05704166
3. fázisFut, nem toboroz
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
Where
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Huai'an, Nanchang, Shanghai, Taizhou, Ürümqi, Wenzhou, Wuhan, Xiamen, Yangzhou, Zhengzhou
Életkor
18 év and over
People
851 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06422143 · EU 2023-510128-66-00
3. fázisTaking people
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Where
Beijing, Changchun, Changde, Changsha, Chengdu, Chongqing, Dalian, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Linhai, Linyi, Nanchang, Ningbo, Shanghai, Shenyang, Shenzhen, Taiyuan, Tianjin, Wenzhou, Wuhan, Xi'an, Yangzhou, Yueyang, Zhengzhou
Életkor
18 év and over
People
1160 worldwide
Run by
AstraZeneca
See details and how to joinNCT06692738 · EU 2024-514281-39-00
2. fázisTaking people
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Where
Beijing, Changsha, Chengdu, Dongguan, Henan, Hubei, Shanghai, Shenyang, Wuhan, Xi'an, Xinxiang, Xuzhou
Életkor
18 év and over
People
750 worldwide
Run by
DualityBio Inc.
See details and how to joinNCT06953089 · EU 2025-523895-22-00
2. fázisTaking people
Phase II Clinical Study of Probiotic LR607 in Patients With Non-Small Cell Lung Cancer
Where
Guangzhou
Életkor
18 év to 80 év
People
46
Run by
Zhujiang Hospital
See details and how to joinNCT07534033
3. fázisTaking people
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
Where
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Jining, Kunming, Lanzhou, Linhai, Linyi, Nanjing, Nanning, Shanghai, Shenyang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xi'an, Yangzhou, Zhengzhou
Életkor
18 év and over
People
675 worldwide
Run by
AstraZeneca
See details and how to joinNCT06357533 · EU 2023-505077-32-00
3. fázisTaking people
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
Where
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Jingzhou, Kunming, Linhai, Nanchang, Ningbo, Shanghai, Wenzhou, Wuhan, Xi'an, Xiangyang, Zhengzhou
Életkor
18 év and over
People
1160 worldwide
Run by
AstraZeneca
See details and how to joinNCT06627647 · EU 2024-515008-38-00
1/2. fázisTaking people
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
Where
Chengdu, Chongqing, Deyang, Fuzhou, Guangzhou, Jinan, Shanghai, Shenyang, Shenzhen, Wuhan
Életkor
18 év and over
People
152 worldwide
Run by
AstraZeneca
See details and how to joinNCT06996782 · EU 2024-519786-22-01
1/2. fázisTaking people
Phase I/II Study of PLB1004 Combined With Platinum-based Doublet Chemotherapy in Patients With EGFR Mutation-positive
Where
Shanghai, Zhengzhou
Életkor
18 év and over
People
108
Run by
Avistone Pharmaceutical（Ningbo）Co., LTD.
See details and how to joinNCT07063329
2. fázisTaking people
Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study
Where
Beijing, Changchun, Changsha, Chengdu, Foshan, Fuzhou, Guangzhou, Harbin, Hefei, Jinan, Kunming, Nanchang, Qingdao, Shanghai, Taiyuan, Wenzhou, Xuzhou
Életkor
18 év and over
People
60
Run by
AstraZeneca
See details and how to joinNCT07295821